pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
TREMFYA · news · pharmadog
← back to TREMFYA
News mentioning TREMFYA
12
stories
4d
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
7d
6 immunology targets to sustain a mammoth I&I market
biospace
27d
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Aug 10, 26
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
May 29, 26
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
endpoints
May 6, 26
Avalo shares spike on skin drug data; BioNTech to cut staff
biopharma dive
May 5, 26
J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
endpoints
May 5, 26
STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
stat
May 5, 26
STAT+: Johnson & Johnson advances IBD therapy, despite trial miss
stat
